New rheumatoid arthritis drug candidate passes first safety check in healthy volunteers
NCT ID NCT06883695
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called SHR-3045 in 40 healthy adults. The study was randomized, double-blind, and placebo-controlled, meaning some participants got the drug and some got a dummy shot. The main goal was to see if the drug causes any side effects and how the body processes it. This is a first step toward possibly treating rheumatoid arthritis, but much more research is needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-3045
What this could lead to
If this drug proves safe and effective in future trials, it could become a new treatment option for rheumatoid arthritis.
What could go wrong
This is a very early phase 1 study in only 40 healthy people, not patients. It only looks at safety and how the drug moves through the body, not whether it works for arthritis. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, 200080, China